New strength of Stalevo

Orion has launched a new strength of Stalevo which contains 200mg levodopa, 50mg carbidopa and 200mg entacapone.

Stalevo is indicated for the treatment of patients with Parkinson’s disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa carboxylase inhibitor treatment.

The additional strength has been launched to provide greater dosage flexibility to prescribers.

View Stalevo drug record

Further information: Orion

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

NICE recommends 'innovative' treatment for type I diabetes

NICE recommends 'innovative' treatment for type I diabetes

Dapagliflozin (Forxiga) has been approved for routine...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Elleste Duet, Elleste Solo, Diprosone and Livial.

Potentially addictive medicines 'being prescribed for years'

Potentially addictive medicines 'being prescribed for years'

Hundreds of thousands of people are receiving prescriptions...

Calcium and Vitamin D Supplements for Osteoporosis

Calcium and Vitamin D Supplements for Osteoporosis

Formulations, doses and costs of osteoporosis supplements.